SIMVASTATIN for PCOS
Simvastatin is a Phase 3 clinical candidate for PCOS acting via inhibition of HMG-CoA reductase.
Hypothesized mechanism
By inhibiting HMG-CoA reductase, simvastatin reduces cholesterol/steroidogenic substrate availability, potentially lowering androgen synthesis and improving the dyslipidemic profile of PCOS.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 5 of 10 overall, a emerging reading, from a pathway rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Only a single line of evidence is present: an Open Targets database entry stating simvastatin is a Phase 3 clinical candidate for PCOS acting on HMG-CoA reductase. No independent mechanistic lines (e.g., separate biochemical, genetic, or animal studies) converge here.
Rigor
The claim cites a clinical-stage designation (Phase 3) from Open Targets, which implies human-relevant testing, but no actual study data, model, or outcomes are provided. This is a database annotation rather than a recent mechanistic study, limiting rigor.
Specificity
The drug's action is specified precisely as HMG-CoA reductase inhibition on the target 3-hydroxy-3-methylglutaryl-CoA reductase, a well-defined molecular target. Simvastatin is a highly selective statin for this enzyme.
Plausibility
HMG-CoA reductase inhibition addresses the dyslipidemia and possibly hyperandrogenism components of PCOS, giving a partial target-phenotype fit. However, the claim itself provides no explicit mechanistic linkage between HMG-CoA reductase and PCOS pathophysiology.
Consistency
With only one claim, there are no multiple mechanistic signals to assess for agreement. The single signal is internally coherent (clinical candidate with a defined target) but cannot demonstrate convergence.
Independent reading, reported beside the score
One outside model cross-reference is reported alongside the composite score. It is recorded separately and is not combined into the score.
MATRIX cross-reference Top 1%
Every Cure’smachine-learned treatment-probability model, drawn from a biomedical knowledge graph across roughly 1,800 drugs and 22,000 diseases. It provides a model-based estimate of how plausible a drug-disease link is given the structure of biomedical knowledge, reported alongside the substrate’s own evidence.
For this pair. MATRIX places this pair at Top 1%, with a treat-score of 4.08 (higher is better; across the pairs we cover, scores span about 3.1 to 4.5).
Scored over MATRIX’s own entities, confirming the same drug and disease: CHEBI:9150 (drug) and MONDO:0008487 (disease). Validate against the source: Every Cure’s MATRIX dataset ↗.
More on the MATRIX cross-reference and its provenance →Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), SIMVASTATIN (a Small molecule) is a clinical candidate for PCOS (maximum clinical stage PHASE_3); its mechanism of action is HMG-CoA reductase inhibitor on target 3-hydroxy-3-methylglutaryl-CoA reductase. Open Targets · mechanistic ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →